Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine
Autore:
Morrey, JD; Bailey, KW; Korba, BE; Sidwell, RW;
Indirizzi:
Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 nst Antiviral Res, Logan, UT 84322 USA Georgetown Univ, Div Mol Virol & Immunol, Rockville, MD USA Georgetown Univ Rockville MD USA Mol Virol & Immunol, Rockville, MD USA
Titolo Testata:
ANTIVIRAL RESEARCH
fascicolo: 2, volume: 42, anno: 1999,
pagine: 97 - 108
SICI:
0166-3542(199906)42:2<97:UOTMRH>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
GENE-EXPRESSION; INTERFERON-ALPHA; MOUSE MODEL; IN-VIVO; INFECTION; DNA; ANTIGEN; POLYMERASE; INHIBITION; GENOME;
Keywords:
lamivudine; hepatitis B virus; transgenic mice; small animal chemotherapeutic model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Morrey, JD Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 al Res, Logan, UT 84322 USA
Citazione:
J.D. Morrey et al., "Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine", ANTIVIR RES, 42(2), 1999, pp. 97-108

Abstract

A recently developed transgenic mouse strain which expresses high levels of hepatitis B virus (HBV) was studied as a model for evaluation of potential chemotherapeutic agents. Lamivudine ([-]2'-deoxy-3'-thiacytidine), known to reduce hepatitis B viremia in human patients, and zidovudine (3'-azido-3'-deoxythymidine), previously shown to be ineffective for HBV infections inman, were used in parallel in this transgenic animal model. Orally administered lamivudine at dosages of 100, 50, and 25 mg/kg per day given once a day for 21 days significantly decreased serum and liver HBV DNA titers in a dose-responsive manner. Zidovudine (similar to 22 mg/kg per day) administered in the drinking water for 21 days was not effective in reducing these HBV parameters as compared to transgenic placebo-treated controls. The serum HBV DNA titers rebounded to high levels 1 week after cessation of lamivudine treatment. Male and female mice responded in a similar manner to these therapies. The results using this transgenic mouse model were similar to whatwould be predicted from treatment of HBV-infected human patients with lamivudine and zidovudine, and indicate these mice may be useful as a small animal chemotherapeutic model for study of potential HBV inhibitors. (C) 1999 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 21:18:35